A comparison of medetomidine and its active enantiomer dexmedetomidine when administered with ketamine in mice by Burnside WM et al.
 Newcastle University ePrints 
 
Burnside WM, Flecknell PA, Cameron AI, Thomas AA. A comparison of 
medetomidine and its active enantiomer dexmedetomidine when 
administered with ketamine in mice. BMC Veterinary Research 2013, 9: 48 
 
Copyright: 
© 2013 Burnside et al.; licensee BioMed Central Ltd.  
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
DOI link to article: 
http://dx.doi.org/10.1186/1746-6148-9-48 
Date deposited:   2nd September 2014 
 
 
 
 
This work is licensed under a Creative Commons Attribution 2.0 Generic License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
Burnside et al. BMC Veterinary Research 2013, 9:48
http://www.biomedcentral.com/1746-6148/9/48RESEARCH ARTICLE Open AccessA comparison of medetomidine and its active
enantiomer dexmedetomidine when
administered with ketamine in mice
Wesley M Burnside1,2, Paul A Flecknell1, Angus I Cameron3 and Aurélie A Thomas1*Abstract
Background: Medetomidine-ketamine (MK) and dexmedetomidine-ketamine (DK) are widely used to provide
general anaesthesia in laboratory animals, but have not been compared directly in many of these species, including
rodents. This study aimed to compare the onset and depth of anaesthesia, and changes in vital signs, after
intraperitoneal (IP) or subcutaneous (SC) administration of ketamine (75 mg kg-1) combined with medetomidine
(1 mg kg-1) or dexmedetomidine (0.5 mg kg-1) using a randomised semi-crossover design with ≥ 48 hours between
treatments in 10 male and 10 female mice. Each mouse was anaesthetised twice using the same administration
route (IP or SC): once with each drug-ketamine combination. Anaesthetised mice were monitored on a heating pad
without supplemental oxygen for 89 minutes; atipamezole was administered for reversal. The times that the
righting reflex was lost post-injection and returned post-reversal were analysed using general linear models. Tail-
pinch and pedal reflexes were examined using binomial generalized linear models. Pulse rate (PR), respiratory rate
(fr), and arterial haemoglobin saturation (SpO2) were compared using generalized additive mixed models.
Results: There were no significant differences among treatments for the times taken for loss and return of the
righting reflex, or response of the tail-pinch reflex. The pedal withdrawal reflex was abolished more frequently with
MK than DK over time (P = 0.021). The response of PR and SpO2 were similar among treatments, but fr was
significantly higher with MK than DK (P ≤ 0.0005). Markedly low SpO2 concentrations occurred within 5 minutes
post-injection (83.8 ± 6.7%) in all treatment groups and were most severe after 89 minutes lapsed (66.7 ± 7.5%). No
statistical differences were detected in regards to administration route (P ≤ 0.94).
Conclusions: This study failed to demonstrate clinical advantages of the enantiomer dexmedetomidine over
medetomidine when combined with ketamine to produce general anaesthesia in mice. At the doses administered,
deep surgical anaesthesia was not consistently produced with either combination; therefore, anaesthetic depth
must be assessed before performing surgical procedures. Supplemental oxygen should always be provided during
anaesthesia to prevent hypoxaemia.
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Injectable anaesthesia is often considered the method of
choice for experimental procedures in small rodents [1].
Alpha-2 agonists are routinely used in combination with
other drugs to produce anaesthesia. One benefit of α2 ago-
nists is that their effects can be reversed using a specific
antagonist, atipamezole [2]. Of these agents, medetomidine
is a popular choice in various species due to its high α2 re-
ceptor selectivity compared to romifidine, detomidine, and
xylazine. Medetomidine, a racemate of the stereoisomers
levomedetomidine and dexmedetomidine, is a sedative and
analgesic that acts centrally on α2 adrenergic receptors
largely concentrated in the locus coeruleus of the brain
stem to decrease sympathetic tone. Peripherally, medeto-
midine activates postsynaptic α2 adrenergic receptors in
vascular smooth muscle to cause vasoconstriction. Its
main side effects include bradycardia, hypotension, respira-
tory depression, hypothermia and diuresis [3-7]. Hypoten-
sion is a result of centrally mediated effects on sympathetic
tone that may be apparent after the initial peripheral va-
soconstrictive effects pass [2,8-10]. This phenomenon is
also observed during the administration of other α2 ago-
nists [11,12].
Dexmedetomidine has been identified as the active en-
antiomer of medetomidine, yet the effects of levomede-
tomidine have been debated. Unlike medetomidine and
dexmedetomidine, levomedetomidine alone does not ap-
pear to have effects on the cardiovascular system and only
provides sedation or analgesia at high doses in rats and
mice [3]. Its clearance is four times more rapid in the dog
[13]. A second study in the dog compared a high dose and
low dose of levomedetomidine by administration of an ini-
tial intravenous (IV) bolus (10 or 80 μg kg-1) followed by
two-hour constant rate infusions of levomedetomidine
alone (25 or 200 μg kg-1 h-1) with or without a single dose
dexmedetomidine (10 μg kg-1); the study concluded that
the combined administration of a high dose of levome-
detomidine and dexmedetomidine significantly reduced
sedation scores and increased the incidence of bradycardia
[14]. In human cell culture, levomedetomidine was de-
scribed as an “inverse” agonist because it uncoupled active
α2 adrenergic receptors by decreasing [Ca
2+] and inhi-
biting cAMP function [15]. It has been suggested that the
sedative effects of dexmedetomidine alone may therefore
be more predictable and the cardiovascular side effects
should be minimised compared to the racemic mixture.
However, no significant difference was observed when
levomedetomidine was co-administered with dexme-
detomidine until levomedetomidine exceeded eight times
the normal racemic preparation [13]. Although some
studies have suggested that dexmedetomidine is superior
to medetomidine [13,16], this may not be the case.
A handful of studies have compared the sedative ef-
fects of medetomidine and dexmedetomidine in themouse and rat [3], dog [13,17,18], cat [16,19,20], and
sheep [10]. All of these studies except two concluded
there were no clinical advantages of dexmedetomidine
over medetomidine [13,16]. Although there were no
significant differences, one study concluded that
“dexmedetomidine tended to be slightly more potent
than the equivalent dose of medetomidine” and may
provide more predictable sedation and analgesia in the
dog [13]. A more recent comparison reported signifi-
cantly greater muscle relaxation in medetomidine-
treated cats [16].
Ketamine in combination with medetomidine (MK)
has been widely used as an anaesthetic for laboratory
rats and mice [1,7,21-24]. Ketamine is a centrally acting
NMDA-receptor antagonist that rapidly induces dis-
sociative anaesthesia while providing analgesia. Its side
effects include tachycardia, dysphoria, and muscle rigi-
dity. When combined with an α2 agonist, general anaes-
thesia may be attained. The muscle relaxant properties
of the α2 agonist offset the rigidity induced by ketamine
and co-administration decreases the effective dose of
each drug [5-7].
The introduction of dexmedetomidine as a veterinary
product has been accompanied by the withdrawal of
medetomidine in some countries (e.g. the USA). Conse-
quently, use of dexmedetomidine in combination with
ketamine (DK) has increased, with dose rates based on
assumptions of potency derived from the relatively few
studies in other species. Because dexmedetomidine was
identified as the active enantiomer of medetomidine, the
dose of dexmedetomidine administered is normally half
that of the medetomidine; this is due to the absence of
levomedetomidine that comprises 50% of the medetomi-
dine racemate. Three studies in other species adminis-
tered equal amounts of ketamine combined with doses
of medetomidine or dexmedetomidine assumed by the
researchers to be equipotent. A study of the golden-
headed lion tamarin Leontopithecus chrysomelas con-
cluded that DK provided greater anaesthetic depth be-
cause the length of time it took tamarins treated with
DK to walk after standing was significantly greater [25].
Similarly, a field experiment in the Chinese water deer
Hydropotes inermis also observed a more rapid recovery
with MK, as well as significantly faster immobilisation
[26]. There were no significant differences between MK
and DK when administered to the Bennett’s wallaby
Macropus rufogriseus [27]. Although these studies sup-
port interspecies variation in response to MK and DK
administration, currently there appear to be no data dir-
ectly comparing MK and DK in laboratory rodents.
This study aimed to compare the onset and depth of
anaesthesia, and changes in vital signs, after intraperito-
neal (IP) or subcutaneous (SC) administration of MK or
DK combinations in mice.
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Animals
Twenty C57BL/6N mice, 10 male and 10 female were ac-
quired from a commercial breeder (Charles River UK Ltd.,
Kent, UK). These mice were acclimated two weeks prior
to the study in an animal room maintained at 22 ± 1°C
and 35% humidity, on a 12-hour light-dark cycle (begin-
ning at 07:00) with 15 to 20 air changes hour-1; regular
serological monitoring ensured this facility is free from all
recognised respiratory pathogens of rodents. A positive-
pressure individually ventilated cage system (Maxiseal,
Arrowmight, Hereford, UK) was used to house a maxi-
mum of six same-sex mice cage-1. Each cage contained
aspen woodchip bedding (BS&S Ltd., Edinburgh, UK) and
nesting material (shredded paper, DBM Food Hygiene
Supplies Ltd., Broxburn, UK). Food (CRM (P), Special
Diets Services, Essex, UK) and tap water were provided
ad libitum. At the time of the study, the mice were 6
weeks old and ear notched for identification; males
weighed 23 ± 1.4 g and females weighed 19 ± 0.7 g.
Experimental design
Four anaesthetic treatments were evaluated by a ran-
domised semi-crossover design with ≥ 48 hours between
treatments. Ketamine (75 mg kg-1, Ketalar™ Injection,
Pfizer Ltd., Sandwich, UK) was combined with medeto-
midine (1 mg kg-1, DomitorW, Janssen Animal Health,
Basingstoke, UK) or dexmedetomidine (0.5 mg kg-1,
DexdomitorW, Janssen Animal Health). Each mouse was
randomly anaesthetised with one drug-ketamine com-
bination (e.g. medetomidine) administered by the IP or
SC route; after a minimum of 48 hours, each mouse was
anaesthetised again with the other drug-ketamine com-
bination (e.g. dexmedetomidine) administered by the
same route as its first treatment. Data were collected
from 06 to 17 June 2011 between 9:00 and 13:00 daily to
ensure time of day did not affect results. No more than
three mice were concurrently anesthetised to allow
enough time to monitor each individual; the injection of
each mouse was staggered by 5 minutes. The same oper-
ator collected all the data obtained in this study.
This study was carried out in accordance with project
and personal licenses granted under the United Kingdom’s
Animals (Scientific Procedures) Act (1986) and the
Newcastle University Ethical Review Committee specific-
ally approved this study (PPL 60/4126).
Procedure
The time from injection to loss of the righting reflex
(LORR) was recorded when the mouse appeared immo-
bile and was physically rolled into lateral recumbency by
hand to verify that the righting reflex was abolished.
Each mouse was placed on a digital thermoregulatedheating pad (37°C, 507220F, Harvard Apparatus, Kent,
UK) to breathe room air; protective eye lubricant was
applied (PuralubeW, Pharmaderm, Melville, NY, USA).
The hair of the right thigh was clipped and a pulse oxi-
meter (MouseOxW, Starr Life Sciences Corp., Oakmont,
PA, USA) probe was placed to monitor pulse rate (PR)
and arterial haemoglobin saturation (SpO2). In addition
to PR and SpO2, the tail-pinch and pedal withdrawal re-
flexes (presence or absence determined “by hand”), and
respiration rate (fr; determined by observation of chest
wall movement) were monitored for 89 minutes from 5
minutes post-injection at 7-minute intervals. The PR
and SpO2 were averaged from values collected every 0.2
seconds (MouseOxW) over a 30-second time interval for
each sample time point. Regardless of any parameters,
the effects of medetomidine or dexmedetomidine were
antagonised at 89 minutes post-injection by atipamezole
(5 mg kg-1, AntisedanW, Janssen Animal Health) admin-
istered by the same route as induction. The time until
return of the righting reflex (RORR) was recorded as the
time from atipamezole administration until the mouse
rolled unassisted from lateral to ventral (sternal) recum-
bency. Then, mice were placed in a fan-assisted incuba-
tor (25°C, MediHeat™, Peco Servies Ltd., Cumbria, UK)
until full recovery.Statistical analysis
General linear models (glms) were used to analyse the
times until LORR and RORR. The full models included
drug, administration route, bodyweight, and sex as ex-
planatory variables with drug and administration route
included as an interaction term. The optimal model was
determined by the stepwise removal of variables to reach
the lowest Akaike’s information criterion (AIC). A re-
duction of ≥ 5 in AIC was considered indicative of a sig-
nificant improvement in model fit.
The presence of tail-pinch and pedal withdrawal re-
flexes was evaluated with generalized linear models
(GLMs). Models included a binomial error structure to
account for the binary nature of the response variable.
Explanatory variables in the full model included drug,
administration route, and time each measurement was
taken, with drug and administration route included as
an interaction term. Stepwise removal of variables was
used to determine the optimal model. Model residuals
were examined with an auto-correlation function (acf )
and showed that the pedal withdrawal reflex models
were temporally auto-correlated. Pedal withdrawal reflex
was better explained with a binomial generalized addi-
tive model with an auto-regressive correlation structure
to account for the temporal dependence between resi-
duals. Stepwise removal of variables was used to deter-
mine the optimal model.
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Figure 1 Loss and return of the righting reflex. Mean time
(seconds) until loss of the righting reflex (LORR) and return of the
righting reflex (RORR) after administration of medetomidine-
ketamine (MK) or dexmedetomidine-ketamine (DK) by the
intraperitoneal (IP) or subcutaneous (SC) route. The time to LORR
was not significantly affected by drug (P = 0.29) or administration
route (P = 0.71). Similarly, the time until RORR was not significantly
affected by drug (P = 0.61) or administration route (P = 0.18).
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additive mixed effects models (GAMMs) to allow for po-
tential non-linear relationships among variables as well
as violations of independence within the data. The full
models for each response variable included the other
two response variables as additional explanatory vari-
ables for each model (e.g. the model for PR included fr,
and SpO2). Drug, administration route, time, body-
weight, and sex were also included as explanatory vari-
ables for each of the three response variables. Where an
explanatory variable appeared to demonstrate non-linear
relationships with the response (based on primary visual
assessment of data), they were included as smooth terms
in the full model (Additional file 1). Mouse was included
as a normally distributed random effect to account for
pseudo-replication in the semi-crossover design. Op-
timal models were reached by the stepwise removal of
variables, and replacement of non-significant smooth
terms with linear ones. Final models were tested with
acfs for the presence of temporal auto-correlation. Opti-
mal correlation structures were selected by AIC to cor-
rect for this auto-correlation. All models had this best
accounted for by auto-regressive moving-average cor-
relation structures. These were then applied to the full
model and stepwise removal of explanatory variables
was performed again.
All analyses were performed using R version 2.14.0
(R Foundation for Statistical Computing; http://www.R-
project.org). A significance level of P ≤ 0.05 was used
during interpretation of these analyses and all means are
reported as the mean ± standard deviation in the text.
Results
The time until LORR was not significantly affected by
drug (glm, F = 1.14, P = 0.29), administration route
(glm, F = 0.14, P = 0.71; Figure 1), or individual
bodyweight (glm, F = 3.30, P = 0.078). Similarly, the time
until RORR was not significantly affected by drug (glm,
F = 0.26, P = 0.61), administration route (glm, F = 1.86,
P = 0.18; Figure 1), or individual bodyweight (glm, F = 0.16,
P = 0.69).
Loss of the tail-pinch reflex occurred by 12 minutes
post-injection and did not significantly differ between
MK and DK (GLM, z = 0.92, P = 0.36; Figure 2). Neither
drug consistently achieved loss of the pedal withdrawal
reflex by either administration route, but was more fre-
quent with MK than DK over time (GLM, z = 2.3,
P = 0.021; Figure 2).
Pulse rate was not significantly different between drug
(GAMM, t = 0.48, P = 0.63; Figure 3) or administration
route (GAMM, t = 0.47, P = 0.64), bodyweight (GAMM,
t = 0.008, P = 0.99) or sex (GAMM, t= 1.26, P = 0.21). It
was negatively correlated with time until about 47 mi-
nutes post-injection, and positively correlated thereafter(GAMM, F =16.59, e.d.f. = 6.13, P ≤ 0.0005). Pulse rate
was also positively correlated with SpO2 until about 77%
SpO2, after which the correlation became negative
(GAMM, F = 9.20, e.d.f. = 2.74, P ≤ 0.0005).
The fr was significantly higher with MK than DK
(GAMM, t = 4.047, P ≤ 0.0005; Figure 3). Administration
route did not significantly affect fr (GAMM, t = 0.077,
P = 0.94). The correlation between fr and SpO2 was nega-
tive until approximately 76% SpO2, at which point the cor-
relation becomes positive (GAMM, F = 19.19, e.d.f. = 1.86,
P ≤ 0.0005).
The SpO2 was not affected by drug (GAMM, t = 0.76,
P = 0.45) or administration route (GAMM, t = 1.75,
P = 0.081; Figure 3), but positively correlated with
bodyweight (GAMM, t = 2.85, P = 0.0046) and was signifi-
cantly lower in males than females (GAMM, t = 2.88,
P = 0.0041). The SpO2 was negatively correlated with PR
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Figure 2 Tail-pinch and pedal reflexes. Percentage of individuals
with present tail-pinch and pedal withdrawal reflexes after
administration of medetomidine-ketamine (MK) or
dexmedetomidine-ketamine (DK) over time. Loss of the tail-pinch
reflex did not significantly differ between drug combination (P = 0.36).
Pedal withdrawal reflex loss was not consistently achieved by either
drug combination, but was more frequent with MK than DK over time
(P = 0.021).
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Figure 3 Vital signs. Mean pulse rate (PR) and respiratory rate (fr)
after administration of medetomidine-ketamine (MK) or
dexmedetomidine-ketamine (DK), and arterial haemoglobin
saturation (SpO2) after drug administration by the intraperitoneal (IP)
or subcutaneous (SC) route over time. Although means were not
used to determine statistical significance, they effectively display
data trends.
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P ≤ 0.0005). It was positively correlated with time until
about 47 minutes post-injection and negatively correlated
thereafter (GAMM, F = 50.87, e.d.f. = 2.86, P ≤ 0.0005).
Discussion
Medetomidine and dexmedetomidine are routinely
administered alone or in combination with other drugs
including ketamine; however, to the best of our know-
ledge, only a handful of peer-reviewed studies have
aimed to compare the sedative and analgesic properties
of these drugs alone and even fewer compared their use
in conjunction with ketamine.
Our study found no significant difference in LORR
and RORR times based on drug, administration route, or
individual bodyweight. Loss of the tail-pinch reflex oc-
curred by 12 minutes post-injection in all treatments
and did not significantly differ between MK and DK.
Neither drug consistently achieved loss of the pedal
withdrawal reflex by either administration route, but loss
was more frequent with MK than DK over time. Pulse
rate was not significantly different among treatments,
but fr was significantly higher with MK than DK; admin-
istration route did not significantly affect fr. The SpO2
was not affected by drug or administration route, but
positively correlated with bodyweight and was signi-
ficantly lower in males than females. On average, the SpO2
of the mice was markedly low (<85%) within 5 minutes
post-injection and decreased severely (to < 70%) by
89 minutes.
Many studies that directly compared medetomidine and
dexmedetomidine as a sedative or premedication foundno clinically significant differences in various species
[3,15-19]. In a collection of experiments in laboratory ro-
dents, IV sedation with medetomidine and its enantiomers
were found to induce similar levels of hypotension, brady-
cardia and loss of the mydriatic response; levomedeto-
midine had no cardiovascular or pupillary effect when
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found that all three drugs (0.01 to 1 mg kg-1 medeto-
midine; 0.01 to 0.1 mg kg-1 dexmedetomidine; 0.3 to
10 mg kg-1 levomedetomidine) appeared to inhibit the
acetic acid-induced writhing response in mice. Ultimately,
these studies concluded there were no major differences
between medetomidine and dexmedetomidine [3]. Based
on the results of the writhing test, levomedetomidine may
have analgesic properties. This lack of differences reported
in these previous studies when medetomidine and dexme-
detomidine were administered alone supports our current
findings that there was no apparent clinical difference
between these drugs administered in combination with
ketamine.
The drug dosages used in this study represent com-
monly reported MK combinations administered to mice
[1,7,22-24]. The dexmedetomidine dose (0.5 mg kg-1)
used was calculated as half the medetomidine dose
(1 mg kg-1) because it lacks the levomedetomidine com-
ponent present in the racemic mixture. We therefore
expected the doses of medetomidine and dexmedetomidine
to be equipotent.
The recommended dose of atipamezole to reverse the
effects of these drugs is 5 mg kg-1 for 1 mg kg-1 of
medetomidine or 0.5 mg kg-1 of dexmedetomidine [22],
but its reported quality of reversal is inconsistent [21].
We used the time until RORR as a measure of MK and
DK reversibility by atipamezole; there were no signifi-
cant differences, but there was a wide variation in reco-
very times (293 ± 258 seconds).
Depending on the procedure to be performed, the
ideal anaesthetic depth may vary. In practice, depth of
anaesthesia is generally defined by the loss of specific re-
flexes as the depth of anaesthesia progresses from seda-
tion to surgical anaesthesia. Sedation is the first level; in
mice, locomotion ceases, respiration slows, and the head
and tail are relaxed. Next, light anaesthesia occurs when
the righting reflex is lost, but the mouse will respond to
painful stimuli. Surgical depth of anaesthesia is achieved
when the tail-pinch and pedal withdrawal reflexes are
lost.
Subcutaneous administration of 0.3 mg kg-1 of dexme-
detomidine abolished the righting reflex in rats, but para-
doxical excitability was observed at the 1 mg kg-1 dose;
neither medetomidine nor dexmedetomidine induced sus-
tainable loss of the pedal withdrawal reflex indicating light
anesthesia [3]. Similarly, the doses of MK and DK admi-
nistered in our study induced LORR (89 ± 51 seconds),
but, based on their failure to abolish the pedal withdrawal
reflex throughout the time post-injection, may not provide
appropriate anaesthetic depth suitable for surgical proce-
dures (Figure 2). These findings were consistent with
other reports of MK administration in mice [1,22]. Studies
that compared depth of anaesthesia between MK and DKsuggested that DK produced a greater anaesthetic depth
[25,26]; conversely, our study observed significantly
deeper anaesthesia from MK (Figure 2). These inconsist-
ent findings could be due to species differences among
mice, golden-headed lion tamarins and Chinese water
deer. Similarly, differences among different strains of the
same species (e.g. a BALB/c or C57BL/6N background in
mice) have been reported in the field of analgesia and an-
aesthesia [28-31].
Normal resting PR in the mouse ranges from 350 to
600 beats minute-1 [32]. Bradycardia was apparent for
approximately 26 minutes post-injection when the ave-
rage PR reached a minimum (236 ± 35 beats minute-1);
the PR steadily increased thereafter (Figure 3). This dra-
matic decrease in PR was attributed to reflex bradycar-
dia, a baroreceptor response that compensates for initial
α2-induced peripheral vasoconstriction and hypertension.
Other studies also found no differences in PR when MK
and DK were compared [26,27]. These well-understood
physiological mechanisms support that the PR responded
as expected when an α2 agonist is administered, while
these studies support that there are no clinical differences
between MK or DK administered IV or SC in mice.
The normal resting fr in the mouse ranges from 80 to
200 breaths minute-1 [32]. The mice treated with DK
(144 ± 17 breaths minute-1) had significantly lower fr
than those treated with MK (156 ± 15 breaths minute-1;
Figure 3), but the difference does not appear to be clin-
ically significant based on the normal resting respiratory
rate and the lack of difference among treatments with
regards to SpO2. The increase in fr over time could be a
combined response to a rapid decrease in arterial partial
pressure of oxygen (PaO2) and potential increase in ar-
terial partial pressure of carbon dioxide (PaCO2). Al-
though PaCO2 is the primary trigger stimulating the
respiratory drive, abnormally low PaO2 (≤ 60 mmHg)
alone can have a role as well, referred to as the “hypoxic
ventilatory response” [33,34]. Direct measurements of
PaO2 and PaCO2 would be necessary to confirm this. On
observation, respiratory patterns of individual mice
appeared shallower over time; this may account for the
steady increase in fr, while the SpO2 continued to de-
crease. Respiratory depression, also known as hypoven-
tilation, caused by α2 agonists was suspected in this
study because depression of the central nervous system
following the activation of α2 agonist receptors includes
depression of respiratory centres. [4,6,35]. Measure-
ments of tidal volume and end-tidal carbon dioxide of
the mice would be necessary to confirm this. The effect
of MK and DK on fr in other studies was inconsistent
[25-27]. This lack of consistency could be also attributed
to variation among species, or may require further
examination to verify the physiological process that oc-
curred in our study.
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treatment groups, there was an interesting relationship
between sex and bodyweight. Although a significant posi-
tive correlation existed between SpO2 and bodyweight,
male mice had a significantly lower SpO2 than females. An
autocorrelation exists between sex and weight: under nor-
mal circumstances in mice of a given age, males have a
predictably greater bodyweight than females; however, an
unknown component of sex sets the average SpO2 of male
mice lower than females. A study in rats suggested that
females may have a more efficient oxygen transport sys-
tem than males related to a higher pulmonary compliance
[36], while another found that virgin female rats at the on-
set of sexual maturity have a greater gas-exchange surface
area than male rats [37]. In our study, a greater pulmonary
compliance of prepubescent female mice could contribute
to the significant differences observed between sexes. A
specific study would be required to further explain the
relationship we observed in mice and determine if males
and females have different requirements for oxygen under
anaesthesia.
Hypoxaemia is a significant cause of mortality in
anesthetised mice, yet supplemental oxygen is not com-
monly used [7]. In order to mimic common laboratory
practice, supplemental oxygen was not supplied in this
study. The SpO2 was markedly low within 5 minutes
post-injection (83.8 ± 6.7%) and decreased severely to
66.7 ± 7.5% by 89 minutes (Figure 3). Although hypox-
aemia was anticipated based on previous studies, SpO2
levels were lower than expected [25-27]. This large de-
crease in SpO2 could be due the monitoring method
employed in our study: pulse oximetry.
Pulse oximetry was used in this study because it
provides a simple, non-invasive means of monitoring
respiratory function; however, pulse oximetry has limita-
tions. Readings become less reliable at lower oxygen sa-
turation levels (< 70 to 75%) [38,39]. This is not usually
a significant problem because levels less than 80% re-
quire corrective action when supplemental oxygen is not
supplied; this threshold increases to 90% for individuals
receiving supplemental oxygen. Additionally, peripheral
vasoconstriction and hypothermia, side effects of mede-
tomidine, could have prevented accurate readings due to
a lack of perfusion in the location of the probe [4-7].
Although we did not monitor core temperature, the
heating pad used throughout the experiment should
have helped to prevent hypothermia. In a previous study
in rats, the pulse oximeter readings were comparable to
arterial blood gas values [40]. Other sources of error
could include mechanical artifacts from improper probe
placement and electromagnetic interference, but are less
likely [39].
There were no significant differences between IP and
SC administration as the times of onset and anaestheticdepths were similar. This was unexpected because IP ad-
ministration was anticipated to result in a more rapid
onset, greater first pass extraction of the anaesthetic
agents by the liver, and possible consequent reduction in
efficacy based on previous work [41]. Despite this poten-
tial uncertainty as to dose equivalence, SC dosing may
be considered preferable to prevent additional stress to
the animal, as well as potential damage to internal
organs that may occur by IP delivery; it may also be
more a more reliable route because IP injections have
been associated with a high partial failure rate [42].
The rigorous statistical model selection employed en-
sured that a dynamic and flexible co-variance structure
was appropriately applied to the error structures of time-
series models. Mouse was included as a random effect to
account for the lack of independence that resulted from
subjecting each mouse to both drug combinations (the
semi-crossover design). Appropriate model error struc-
tures accounted for the repeated measures taken se-
quentially from each mouse. The semi-crossover design
allowed us to reduce the number of animals required for
the study, reuse mice for multiple treatments, and account
for physiological differences among individuals. Because
of the lack of independence between time points within
these data (as for any analysis of a time-series), displaying
mean values for each time-point can only be used to dem-
onstrate overall data trends (Figure 3). More difficult to
interpret graphically and beyond the scope of this study,
the appropriate plots demonstrating the statistical nature
of these relationships required individual plots for each
mouse (Additional file 2).
The statistical analyses of related previous work have re-
lied heavily on repeated measures analysis of variance
(ANOVA) [13,14,19,25-27,43]. While these tests account
for a degree of dependence between data points, the
mixed effects modeling approach we utilised is more fle-
xible and robust than more common analyses. Whereas a
repeated measures ANOVA can be used to detect linear
dependencies between response and explanatory variables,
the models used here can be used to explain non-linear
autocorrelation (e.g. a decay in dependence as time bet-
ween data points increases) [44,45]. Modern data analysis
techniques could be used to refine experimental protocol
and more powerful methodologies could be encouraged in
laboratory animal medicine to reduce the numbers of
individuals used in studies.
Our study failed to demonstrate clinical differences in
the use of MK or DK administered either IP or SC in
the mouse. We also demonstrated the need for appro-
priate oxygen supplementation, even during short or
minor procedures. Further research should examine the
effects of MK and DK in different mouse strains. Blood
pressure monitoring may have demonstrated the rela-
tionship between the initial hypertension expected from
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and the initial bradycardia observed. Then, the centrally
mediated decrease in blood pressure reported to follow
may correlate with the steady increase in PR which oc-
curred after 26 minutes post-injection [2,8-12]. A mea-
sure of rectal temperature would ensure the heating pad
was appropriately maintaining body temperature.
Conclusions
Our study failed to demonstrate clinical advantages of the
active enantiomer dexmedetomidine over the racemic
mixture medetomidine when combined with ketamine for
general anaesthesia in mice. These results reassure col-
leagues working in locations where medetomidine is no
longer available that dexmedetomidine can be used with a
50% reduction in dose rate. The doses of MK and DK
administered in this study did not consistently produce
deep surgical anaesthesia, so anaesthetic depth must be
assessed before performing surgical procedures. There
was no advantage of the IP administration route com-
pared to the SC injection, but the SC route may be sug-
gested based on previous reports of reduced injury, stress
and partial failure rates [42]. Because the SpO2 levels of all
anaesthetised mice were markedly or severely low
throughout this study, supplemental oxygen should always
be provided regardless of the length of the procedure.Additional files
Additional file 1: Smoothing curves for non-linear relationships.
Estimated smoothing curves of the non-linear parameters of the effect of
time on pulse rate (PR) and arterial haemoglobin saturation (SpO2), as
well as the effect of SpO2 on PR and respiratory rate (fr) determined by a
series of generalized additive mixed effects models (GAMMs). Dashed
lines represent 95% CI. Significant non-linear relationships occurred for PR
(P ≤ 0.0001) and SpO2 (P < 0.0001) as a smoothing function of time, as
well as PR (P ≤ 0.0001) and fr (P < 0.0001) as a smoothing function of
SpO2.
Additional file 2: Plots of vital signs for individual mice. Individual
plots of pulse rate (PR), respiratory rate (fr) and arterial haemoglobin
saturation (SpO2) for each mouse by after administration of
medetomidine-ketamine (MK) or dexmedetomidine-ketamine (DK) by the
intraperitoneal (IP) or subcutaneous (SC) route over time used for
statistical analysis. The individual mouse identification number is located
at the bottom left corner of each plot.Abbreviations
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models; GLMs: Generalized linear models; IP: Intraperitoneal; IV: Intravenous;
LORR: Loss of the righting reflect; MK: Medetomidine-Ketamine;
PaCO2: Arterial partial pressure of carbon dioxide; PaO2: Arterial partial
pressure of oxygen; PR: Pulse rate; RORR: Return of the righting reflex;
SC: Subcutaneous; SpO2: Arterial haemoglobin saturation.Competing interests
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